The World Health Organisation should review its approval of a drug used to prevent life-threatening bleeding in women in childbirth because there is not enough evidence that it is effective, a study published on Monday said. Research published in the Journal of the Royal Society of Medicine said the evidence to support the use of misoprostol is “at best inconclusive”, yet it is increasingly used in poorer countries to prevent postpartum hemorrhage (PPH).
